EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Guggulsterone Alleviates Atherosclerosis in ApoE-/- Mice by Modulating Lipid Metabolism and Inflammatory Responses Associated with Modulation of the Srebp2/Hmgcr Signaling Axis

Jialin Liang, Jingfang Zhang, Xun Huang, Jiahui Xu, Xinyu Luo, Jiaying Zhang, Cheng Huang, Kunhui He

Die Pharmazie · 25.06.2026 · 81 (6)

DOI: 10.31083/pharmazie52690 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Die Pharmazie, online erschienen am 25.06.2026. Verfasst von Jialin Liang und 7 weiteren Autor:innen. Beteiligte Einrichtung: The First Clinical Medical School, Changsha Medical University, 410219 Changsha, Hunan, China. Hauptthemen laut MEDLINE: Atherosclerosis, Lipid Metabolism, Inflammation, Pregnenediones. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Educational Department of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective:Atherosclerosis (AS) is a chronic inflammatory vascular disease characterized by dysregulated lipid homeostasis and plaque formation. Consequently, there is an ongoing need for therapies with high efficacy and low toxicity. Thus, this study aimed to investigate the effects of guggulsterone (GS) on atherosclerotic plaques in mice and to elucidate the molecular mechanisms underlying the beneficial effects of GS in this pathological context.Methods:A total of 53 male ApoE-/- knockout mice were fed on a high-fat Western-type diet for 8 consecutive weeks to induce atherosclerotic lesions; three mice were randomly selected for model validation by serum lipid analysis and histopathological examination, and were excluded from subsequent grouping. The remaining 50 mice were randomly assigned to five groups (n = 10 per group): model group, low/medium/high-dose GS treatment groups (35/70/140 mg/kg GS, respectively), and an atorvastatin (AT) group (2.6 mg/kg). An additional 10 C57BL/6J mice served as the normal control group. After 8 weeks of intragastric treatment, serum lipid levels (Total cholesterol [TC], Triglycerides [TG], Low-density lipoprotein-cholesterol [LDL], High-density lipoprotein-cholesterol [HDL]) and a composite AS index were analyzed using standard biochemical methods. Serum nitric oxide (NO), monocyte chemoattractant protein-1 (MCP-1), interleukin-6 (IL-6), and prostacyclin (PGI2) levels were measured by enzyme-linked immunosorbent assay (ELISA). Aortic pathological changes were evaluated by hematoxylin and eosin staining, while monocyte/macrophage-specific monoclonal antibody 2 (MOMA-2) and α-smooth muscle actin (α-SMA) expression were evaluated by immunohistochemistry; Aortic Hmgcr and Srebp2 mRNA levels were quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR). Outcome assessments were conducted in a blinded manner.Results:Compared with the control group, the model group exhibited poorer general status, increased body weight, abnormal lipid levels, elevated levels of inflammatory factors, and typical aortic AS pathological changes (all p < 0.05), together with the upregulation of aortic Srebp2 and Hmgcr mRNA levels (all p < 0.05). In contrast, mice in the medium- and high-dose GS groups and the AT treatment group exhibited improved general status, reduced body weight, normalized lipid levels and inflammatory factors, and ameliorated aortic pathological damage, along with the reversal of the molecular changes observed in AS model mice (all p < 0.05). Notably, high-dose GS exerted comparable or even superior regulatory effects versus AT on the levels of TC, TG, LDL, NO, PGI2, IL-6 and MOMA-2.Conclusion:GS treatment reduces atherosclerotic plaque area and delays AS progression in mice, potentially through the regulation of Srebp2/Hmgcr mRNA expression, thereby improving lipid metabolism, inhibiting inflammatory responses, and enhancing autophagy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AtherosclerosisLipid MetabolismInflammationPregnenedionesAnimalsMaleMiceMice, Inbred C57BLSignal TransductionSterol Regulatory Element Binding Protein 2Hydroxymethylglutaryl CoA ReductasesApolipoproteins EMice, KnockoutPlaque, AtheroscleroticDiet, High-FatAtorvastatinLipidsMice, Knockout, ApoEDose-Response Relationship, DrugDisease Models, Animal

Stichwörter der Autor:innen

ApoE knockout miceatherosclerosisguggulsteronelipid metabolism

Substanzen

pregna-4,17-diene-3,16-dioneSterol Regulatory Element Binding Protein 2PregnenedionesHydroxymethylglutaryl CoA ReductasesSrebf2 protein, mouseHmgcr protein, mouseApolipoproteins EAtorvastatinLipids

Autor:innen und Institutionen

  • The First Clinical Medical School, Changsha Medical University, 410219 Changsha, Hunan, China.

Förderung

  • Educational Department of Hunan Province

Zitieren

APA

Liang, J., Zhang, J., Huang, X., Xu, J., Luo, X., Zhang, J., Huang, C., & He, K. (2026). Guggulsterone Alleviates Atherosclerosis in ApoE-/- Mice by Modulating Lipid Metabolism and Inflammatory Responses Associated with Modulation of the Srebp2/Hmgcr Signaling Axis. Die Pharmazie, 81(6). https://doi.org/10.31083/pharmazie52690

Vancouver

Liang J, Zhang J, Huang X, Xu J, Luo X, Zhang J, et al. Guggulsterone Alleviates Atherosclerosis in ApoE-/- Mice by Modulating Lipid Metabolism and Inflammatory Responses Associated with Modulation of the Srebp2/Hmgcr Signaling Axis. Die Pharmazie. 2026;81(6). doi:10.31083/pharmazie52690

BibTeX
@article{Liang2026,
  author = {Liang, Jialin and Zhang, Jingfang and Huang, Xun and Xu, Jiahui and Luo, Xinyu and Zhang, Jiaying and Huang, Cheng and He, Kunhui},
  title = {Guggulsterone Alleviates Atherosclerosis in ApoE-/- Mice by Modulating Lipid Metabolism and Inflammatory Responses Associated with Modulation of the Srebp2/Hmgcr Signaling Axis},
  journal = {Die Pharmazie},
  year = {2026},
  volume = {81},
  number = {6},
  doi = {10.31083/pharmazie52690}
}
Kostenlos starten →